Current status and future perspectives of conservative surgery for adenomyosis

doi:10.3877/cma.j.issn.1674-6899.2026.04.010

Abstract

Abstract:

Adenomyosis is a common benign gynecological disease in women of reproductive age, characterized by the invasion of endometrial glands and stroma into the myometrium, accompanied by hyperplasia and hypertrophy of the surrounding myocytes. Its clinical manifestations mainly include progressively worsening dysmenorrhea, menorrhagia, chronic pelvic pain, and infertility, severely affecting patients' quality of life. Treatment strategies primarily include medical therapy and surgical treatment. For patients with severe symptoms who do not respond to medical therapy or have fertility requirements, surgical treatment is an important option. Radical surgery, i. e., hysterectomy, can cure the disease but deprives patients of fertility and brings about a series of physiological and psychological impacts. Therefore, uterus-preserving conservative surgical approaches are receiving increasing attention. This article aims to systematically review the latest advances in conservative surgical treatment of adenomyosis and provide an outlook on future directions.

Key words: Adenomyosis, Uterus-preserving surgery, Fertility preservation, Minimally invasive surgery

Yi Yu, Hui Mao, Qiwen Yu, Chi Liu, Yizheng Zu, Wanying Chen, Weiwei Wei, Jiming Chen. Current status and future perspectives of conservative surgery for adenomyosis[J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2026, 19(04): 248-253.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6899.2026.04.010

https://zhqjwkzz.cma-cmc.com.cn/EN/Y2026/V19/I04/248

References 65

[1]	Schrager S, Yogendran L, Marquez CM, et al. Adenomyosis: diagnosis and management[J]. Am Fam Physician, 2022, 105(1): 33-38.
[2]	Koh HH, Park E, Kim HS. Mesonephric-like Adenocarcinoma of the Uterine Corpus: Genomic and Immunohistochemical Profiling with Comprehensive Clinicopathological Analysis of 17 Consecutive Cases from a Single Institution[J]. Biomedicines, 2023, 11(8): 2269.
[3]	Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis[J]. F1000Res, 2019, 8: F1000 Faculty Rev-283.
[4]	Antero MF, Ayhan A, Segars J, et al. Pathology and pathogenesis of adenomyosis[J]. Semin Reprod Med, 2020, 38(2-3): 157-166.
[5]	Moldassarina RS. Modern view on the diagnostics and treatment of adenomyosis[J]. Arch Gynecol Obstet, 2023, 308(1): 171-181.
[6]	Benagiano G, Habiba M, Brosens I. The pathophysiology of uterine adenomyosis: an update[J]. Fertil Steril, 2012, 98(3): 572-579.
[7]	Leyendecker G, Kunz G, Herbertz M, et al. Uterine peristaltic activity and the development of endometriosis[J]. Ann N Y Acad Sci, 2004, 1034: 338-355.
[8]	Parazzini F, Vercellini P, Panazza S, et al. Risk factors for adenomyosis[J]. Hum Reprod, 1997, 12(6): 1275-1279.
[9]	Levgur M, Abadi M, Tucker A. Adenomyosis: symptoms, histology, and pregnancy terminations[J]. Obstet Gynecol, 2000, 95(5): 688-691.
[10]	Taran F, Weaver A, Coddington C, et al. Understanding adenomyosis: a case control study[J]. Fertil Steril, 2010, 94(4): 1223-1228.
[11]	Leyendecker G, Kunz G, Noe M, et al. Endometriosis: a dysfunction and disease of the archimetra[J]. Hum Reprod Update, 1998, 4(5): 752-762.
[12]	Gargett CE, Ye L. Endometrial reconstruction from stem cells[J]. Fertil Steril, 2012, 98(1): 11-20.
[13]	Yilmaz BD, Bulun SE. Endometriosis and nuclear receptors[J]. Hum Reprod Update, 2019, 25(4): 473-485.
[14]	Bulun SE, Yildiz S, Adli M, et al. Endometriosis and adenomyosis: shared pathophysiology[J]. Fertil Steril, 2023, 119(5): 746-750.
[15]	Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis[J]. Endocr Rev, 2019, 40(4): 1048-1079.
[16]	Zhang H, Li C, Li W, et al. Research Advances in Adenomyosis-Related Signaling Pathways and Promising Targets[J]. Biomolecules, 2024, 14(11): 1402.
[17]	Selntigia A, Molinaro P, Tartaglia S, et al. Adenomyosis: An Update Concerning Diagnosis, Treatment, and Fertility[J]. J Clin Med, 2024, 13(17): 5224.
[18]	Brown HK, Stoll BS, Nicosia SV, et al. Uterine junctional zone: correlation between histologic findings and MR imaging[J]. Radiology, 1991, 179(2): 409-413.
[19]	Van den Bosch T, Dueholm M, Leone FPG, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group[J]. Ultrasound Obstet Gynecol, 2015, 46(3): 284-298.
[20]	Bazot M, Daraï E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis[J]. Fertil Steril, 2018, 109(3): 389-397.
[21]	Harmsen MJ, Van den Bosch T, de Leeuw RA, et al. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure[J]. Ultrasound Obstet Gynecol, 2022, 60(1): 118-131.
[22]	Harmsen MJ, Trommelen LM, de Leeuw RA, et al. Uterine junctional zone and adenomyosis: comparison of MRI, transvaginal ultrasound and histology[J]. Ultrasound Obstet Gynecol, 2023, 62(1): 42-60.
[23]	Reinhold C, McCarthy S, Bret PM, et al. Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation[J]. Radiology, 1996, 199(1): 151-158.
[24]	Dueholm M, Lundorf E, Hansen ES, et al. Magnetic resonance imaging and transvaginal ultrasonography for the diagnosis of adenomyosis[J]. Fertil Steril, 2001, 76(3): 588-594.
[25]	Huang Y, Zhou Y, Chen H, et al. Changes of serum CA125 and PGE2 before and after high-intensity focused ultrasound combined with GnRH-a in treatment of patients with adenomyosis[J]. Open Med (Wars), 2024, 19(1): 20240928.
[26]	Tang Y, Wen MB, Xiang RM, et al. Serum CA125 as a biomarker for dysmenorrhea in adenomyosis[J]. Int J Gynaecol Obstet, 2023, 163(1): 131-139.
[27]	Khan KN, Fujishita A, Mori T. Pathogenesis of Human Adenomyosis: Current Understanding and Its Association with Infertility[J]. J Clin Med, 2022, 11(14): 4057.
[28]	Kishi Y, Suginami H, Kuramori R, et al. Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification[J]. Am J Obstet Gynecol, 2012, 207(2): 114.e1-114.e7.
[29]	Hashim HA, Elaraby S, Fouda AA, et al. The prevalence of adenomyosis in an infertile population: a cross-sectional study[J]. Reprod Biomed Online, 2020, 40(6): 842-850.
[30]	Zhao Y, Luo S, Liu Y, et al. High intensity focused ultrasound treatment for adenomyosis: comparison of efficacy based on MRI features[J]. Int J Hyperthermia, 2023, 40(1): 2197574.
[31]	Etrusco A, Barra F, Chiantera V, et al. Current Medical Therapy for Adenomyosis: From Bench to Bedside[J]. Drugs, 2023, 83(17): 1595-1611.
[32]	Englander M. Uterine Artery Embolization for the Treatment of Adenomyosis[J]. Semin Intervent Radiol, 2008, 25(4): 387-393.
[33]	Mikos T, Lioupis M, Anthoulakis C, et al. The Outcome of Fertility-Sparing and Nonfertility-Sparing Surgery for the Treatment of Adenomyosis. A Systematic Review and Meta-analysis[J]. J Minim Invasive Gynecol, 2020, 27(2): 309-331.e3.
[34]	Takeuchi H, Kitade M, Kikuchi I, et al. Laparoscopic adenomyomectomy and hysteroplasty: a novel method[J]. J Minim Invasive Gynecol, 2006, 13(2): 150-154.
[35]	Younes G, Tulandi T. Conservative Surgery for Adenomyosis and Results: A Systematic Review[J]. J Minim Invasive Gynecol, 2018, 25(2): 265-276.
[36]	Kwack JY, Seo M, Su Hong J, et al. Advanced laparoscopic adenomyomectomy technique for focal uterine adenomyosis by three-step approach[J]. JSLS, 2022, 26(4): e2022.00055.
[37]	Osada H. Uterine adenomyosis and adenomyoma: the surgical approach[J]. Fertil Steril, 2018, 109(3): 406-417.
[38]	Liu L, Wei W, Tang H, et al. Modified Laparoscopic Inverted Triangle Model for Extended Lesion Resection in the Treatment of Symptomatic Localized Adenomyosis in Women Who Have Completed Childbirth[J]. Clin Exp Obstet Gynecol, 2023, 50(9): 183.
[39]	Osada H, Silber S, Kakinuma T, et al. Surgical procedure to conserve the uterus for future pregnancy in patients suffering from massive adenomyosis[J]. Reprod Biomed Online, 2011, 22(1): 94-99.
[40]	Grimbizis GF, Mikos T, Tarlatzis B. Uterus-sparing operative treatment for adenomyosis[J]. Fertil Steril, 2014, 101(2): 472-487.e8.
[41]	Wu R, Zeng L, Hu Q, et al. Outcome of uterine functional structures protection by fertility preservative PUSH surgery in diffuse adenomyosis[J]. Hum Fertil (Camb), 2023, 26(4): 720-732.
[42]	Kuo HH, Weng CH, Jaiswal A, et al. Performing laparoscopic adenomyomectomy with the four-petal method[J]. Fertil Steril, 2020, 114(6): 1352-1354.
[43]	Givens MB, Lindheim SR, Goodman LR. New approaches in bloom: four-petal adenomyomectomy technique[J]. Fertil Steril, 2020, 114(6): 1195-1196.
[44]	Gkrozou F, Vatopoulou A, Skentou C, et al. Diagnosis and Treatment of Adenomyosis with Office Hysteroscopy—A Narrative Review of Literature[J]. Diagnostics, 2023, 13(13): 2182.
[45]	Munro MG. Endometrial ablation[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 46: 120-139.
[46]	Dedes I, Kolovos G, Fruscalzo A, et al. Radiofrequency Ablation for Adenomyosis[J]. J Clin Med, 2023, 12(9): 3069.
[47]	Cho N, Lee KY, Huh J, et al. Cognitive-enhancing effects of Rhus verniciflua bark extract and its active flavonoids with neuroprotective and anti-inflammatory activities[J]. Food Chem Toxicol, 2013, 58: 355-361.
[48]	Lin XL, Hai N, Zhang J, et al. Comparison between microwave ablation and radiofrequency ablation for treating symptomatic uterine adenomyosis[J]. Int J Hyperthermia, 2020, 37(1): 151-156.
[49]	Nam JH. Pregnancy and symptomatic relief following ultrasound-guided transvaginal radiofrequency ablation in patients with adenomyosis[J]. J Obstet Gynaecol Res, 2020, 46(1): 124-132.
[50]	Stepniewska AK, Baggio S, Clarizia R, et al. Heat can treat: long-term follow-up results after uterine-sparing treatment of adenomyosis with radiofrequency thermal ablation in 60 hysterectomy candidate patients[J]. Surg Endosc, 2022, 36(8): 5803-5811.
[51]	McCausland V. The response of adenomyosis to endometrial ablation/resection[J]. Hum Reprod Update, 1998, 4(4): 350-359.
[52]	de Bruijn AM, Smink M, Lohle PNM, et al. Uterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis[J]. J Vasc Interv Radiol, 2017, 28(12): 1629-1642.e1.
[53]	Zhang L, Rao F, Setzen R. High intensity focused ultrasound for the treatment of adenomyosis: selection criteria, efficacy, safety and fertility[J]. Acta Obstet Gynecol Scand, 2017, 96(6): 707-714.
[54]	Nijenhuis R, Smeets A, Morpurgo M, et al. Uterine artery embolisation for symptomatic adenomyosis with polyzene F-coated hydrogel microspheres: three-year clinical follow-up using UFS-QoL questionnaire[J]. Cardiovasc Intervent Radiol, 2015, 38(1): 65-71.
[55]	Fan TY, Zhang L, Chen W, et al. Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis[J]. Eur J Radiol, 2012, 81(11): 3624-3630.
[56]	Liu Y, Zhang WW, He M, et al. Adverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases[J]. Int J Hyperthermia, 2018, 35(1): 56-61.
[57]	Lee JS, Hong GY, Lee KH, et al. Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid[J]. BJOG, 2017, 124(Suppl 3): 18-22.
[58]	Otonkoski S, Sainio T, Mattila S, et al. Magnetic resonance guided high intensity focused ultrasound for uterine fibroids and adenomyosis has no effect on ovarian reserve[J]. Int J Hyperthermia, 2023, 40(1): 2154575.
[59]	Ribeiro F, Ferreira H. Novel Minimally Invasive Surgical Approaches to Endometriosis and Adenomyosis: A Comprehensive Review[J]. J Clin Med, 2024, 13(22): 6844.
[60]	LeeSY, Lee SR, Song JY. Single-Port Versus Reduced-Port (1＋1) Robotic Myomectomy and Hysterectomy[J]. J Clin Med, 2024, 13(21): 6563.
[61]	Jiang J, Pan Y, Yu J, et al. Laparoscopic adenomyomectomy combined with levonorgestrel-releasing intrauterine system is effective for long-term management of adenomyosis[J]. BMC Womens Health, 2024, 24(1): 28.
[62]	Gao Y, Shan S, Zhao X, et al. Clinical efficacy of adenomyomectomy using "H" type incision combined with Mirena in the treatment of adenomyosis[J]. Medicine (Baltimore), 2019, 98(11): e14579.
[63]	Ziegler N, de Wilde RL. Reduction of adhesion formation after gynaecological adhesiolysis surgery with 4DryField PH-a retrospective, controlled study with second look laparoscopies[J]. J Obstet Gynaecol, 2022, 42(4): 658-664.
[64]	Alkatout I, de Wilde RL, Herrmann J, et al. Adhesion Prevention in Gynecologic Surgery: Guidance and Clinical Experience[J]. J Clin Med, 2024, 13(24): 7517.
[65]	曹杨，孙海，朱花，等. 脐带间充质干细胞胶原支架治疗复发性宫腔粘连的Ⅰ期临床试验[J]. 干细胞研究与治疗，2018, 9(1): 192.

Please choose a citation manager

Content to export